U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C15H21N3O
Molecular Weight 259.3467
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PRIMAQUINE

SMILES

COC1=CC(NC(C)CCCN)=C2N=CC=CC2=C1

InChI

InChIKey=INDBQLZJXZLFIT-UHFFFAOYSA-N
InChI=1S/C15H21N3O/c1-11(5-3-7-16)18-14-10-13(19-2)9-12-6-4-8-17-15(12)14/h4,6,8-11,18H,3,5,7,16H2,1-2H3

HIDE SMILES / InChI
Primaquine is a oral medication used to treat and prevent malaria and to treat Pneumocystis pneumonia. Specifically it is used for malaria due to Plasmodium vivax and Plasmodium ovale along with other medications and for prevention if other options cannot be used. Primaquine is an alternative treatment for Pneumocystis pneumonia together with clindamycin. Primaquine is lethal to P. vivax and P. ovale in the liver stage, and also to P. vivax in the blood stage through its ability to do oxidative damage to the cell. However, the exact mechanism of action is not fully understood. Primaquine is well-absorbed in the gut and extensively distributed in the body without accumulating in red blood cells. Administration of primaquine with food or grapefruit juice increases its oral bioavailibity. In blood, about 20% of circulating primaquine is protein-bound, with preferential binding to the acute phase protein orosomucoid. With a half-life on the order of 6 hours, it is quickly metabolized by liver enzymes to carboxyprimaquine, which does not have anti-malarial activity. Common side effects of primaquine administration include nausea, vomiting, and stomach cramps. Primaquine phosphate is recommended only for the radical cure of vivax malaria, the prevention of relapse in vivax malaria, or following the termination of chloroquine phosphate suppressive therapy in an area where vivax malaria is endemic. Patients suffering from an attack of vivax malaria or having parasitized red blood cells should receive a course of chloroquine phosphate, which quickly destroys the erythrocytic parasites and terminates the paroxysm. Primaquine phosphate should be administered concurrently in order to eradicate the exoerythrocytic parasites in a dosage of 1 tablet (equivalent to 15 mg base) daily for 14 days.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
7.5 µM [IC50]
68.0 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
AABLAQUIN

Approved Use

Treatment and prevention of p. vivax.

Launch Date

9.4668482E11
Curative
PRIMAQUINE

Approved Use

Primaquine phosphate is indicated for the radical cure (prevention of relapse) of vivax malaria.

Launch Date

-5.661792E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
53 ng/mL
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PRIMAQUINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
104 ng/mL
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PRIMAQUINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
66 ng/mL
15 mg 1 times / day multiple, oral
dose: 15 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
PRIMAQUINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
65 ng/mL
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PRIMAQUINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
0.5 μg × h/mL
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PRIMAQUINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1 μg × h/mL
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PRIMAQUINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
443 ng × h/mL
15 mg 1 times / day multiple, oral
dose: 15 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
PRIMAQUINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
468 ng × h/mL
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PRIMAQUINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
5.9 h
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PRIMAQUINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
7.4 h
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PRIMAQUINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
4.3 h
15 mg 1 times / day multiple, oral
dose: 15 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
PRIMAQUINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
4.4 h
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PRIMAQUINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
30 mg 1 times / day steady, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adult
n = 120
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 120
Sources:
Other AEs: Malaise, Headache...
Other AEs:
Malaise (1 patient)
Headache (2 patients)
Nausea (1 patient)
Pyrexia (1 patient)
Vomiting (1 patient)
Dizziness (1 patient)
Asthenia (1 patient)
Pruritus (1 patient)
Haemoglobin decreased (1 patient)
Dyspepsia (1 patient)
Sources:
0.6 mg/kg 1 times / day multiple, oral
Highest studied dose
Dose: 0.6 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.6 mg/kg, 1 times / day
Co-administed with::
(artesunate)
50 mg
Sources:
unhealthy, adult
n = 18
Health Status: unhealthy
Condition: acute, symptomatic Plasmodium vivax malaria
Age Group: adult
Sex: unknown
Population Size: 18
Sources:
Disc. AE: Hematocrit decreased...
AEs leading to
discontinuation/dose reduction:
Hematocrit decreased (4 patients)
Sources:
15 mg 1 times / day steady, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, adult
n = 118
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 118
Sources:
Other AEs: Malaise, Headache...
Other AEs:
Malaise (4 patients)
Headache (2 patients)
Nausea (1 patient)
Decreased appetite (3 patients)
Pyrexia (1 patient)
Vomiting (1 patient)
Dizziness (1 patient)
Asthenia (1 patient)
Arthralgia (1 patient)
Muscle spasms (1 patient)
Dyspnoea exertional (1 patient)
Diarrhoea (1 patient)
Sources:
15 mg 1 times / day steady, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, adult
n = 120
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 120
Sources:
Other AEs: Malaise, Headache...
Other AEs:
Malaise (3 patients)
Headache (1 patient)
Nausea (2 patients)
Pyrexia (1 patient)
Vomiting (1 patient)
Myalgia (2 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Asthenia 1 patient
30 mg 1 times / day steady, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adult
n = 120
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 120
Sources:
Dizziness 1 patient
30 mg 1 times / day steady, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adult
n = 120
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 120
Sources:
Dyspepsia 1 patient
30 mg 1 times / day steady, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adult
n = 120
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 120
Sources:
Haemoglobin decreased 1 patient
30 mg 1 times / day steady, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adult
n = 120
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 120
Sources:
Malaise 1 patient
30 mg 1 times / day steady, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adult
n = 120
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 120
Sources:
Nausea 1 patient
30 mg 1 times / day steady, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adult
n = 120
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 120
Sources:
Pruritus 1 patient
30 mg 1 times / day steady, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adult
n = 120
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 120
Sources:
Pyrexia 1 patient
30 mg 1 times / day steady, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adult
n = 120
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 120
Sources:
Vomiting 1 patient
30 mg 1 times / day steady, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adult
n = 120
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 120
Sources:
Headache 2 patients
30 mg 1 times / day steady, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adult
n = 120
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 120
Sources:
Hematocrit decreased 4 patients
Disc. AE
0.6 mg/kg 1 times / day multiple, oral
Highest studied dose
Dose: 0.6 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.6 mg/kg, 1 times / day
Co-administed with::
(artesunate)
50 mg
Sources:
unhealthy, adult
n = 18
Health Status: unhealthy
Condition: acute, symptomatic Plasmodium vivax malaria
Age Group: adult
Sex: unknown
Population Size: 18
Sources:
Arthralgia 1 patient
15 mg 1 times / day steady, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, adult
n = 118
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 118
Sources:
Asthenia 1 patient
15 mg 1 times / day steady, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, adult
n = 118
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 118
Sources:
Diarrhoea 1 patient
15 mg 1 times / day steady, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, adult
n = 118
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 118
Sources:
Dizziness 1 patient
15 mg 1 times / day steady, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, adult
n = 118
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 118
Sources:
Dyspnoea exertional 1 patient
15 mg 1 times / day steady, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, adult
n = 118
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 118
Sources:
Muscle spasms 1 patient
15 mg 1 times / day steady, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, adult
n = 118
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 118
Sources:
Nausea 1 patient
15 mg 1 times / day steady, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, adult
n = 118
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 118
Sources:
Pyrexia 1 patient
15 mg 1 times / day steady, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, adult
n = 118
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 118
Sources:
Vomiting 1 patient
15 mg 1 times / day steady, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, adult
n = 118
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 118
Sources:
Headache 2 patients
15 mg 1 times / day steady, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, adult
n = 118
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 118
Sources:
Decreased appetite 3 patients
15 mg 1 times / day steady, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, adult
n = 118
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 118
Sources:
Malaise 4 patients
15 mg 1 times / day steady, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, adult
n = 118
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 118
Sources:
Headache 1 patient
15 mg 1 times / day steady, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, adult
n = 120
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 120
Sources:
Pyrexia 1 patient
15 mg 1 times / day steady, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, adult
n = 120
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 120
Sources:
Vomiting 1 patient
15 mg 1 times / day steady, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, adult
n = 120
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 120
Sources:
Myalgia 2 patients
15 mg 1 times / day steady, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, adult
n = 120
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 120
Sources:
Nausea 2 patients
15 mg 1 times / day steady, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, adult
n = 120
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 120
Sources:
Malaise 3 patients
15 mg 1 times / day steady, oral
Recommended
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, adult
n = 120
Health Status: unhealthy
Condition: Plasmodium vivax parasite
Age Group: adult
Sex: M
Population Size: 120
Sources:
Overview

OverviewOther

Drug as perpetrator​Drug as victim

Drug as victim

Tox targets
PubMed

PubMed

TitleDatePubMed
Potentiation of the curative action of primaquine in vivax malaria by quinine and chloroquine.
1955 Aug
Methemoglobinemia provoked by malarial chemoprophylaxis in Vietnam.
1968 Nov 21
Simultaneous drug reactions in the same patient. Chloroquine-Primaquine sensitivity.
1970 Apr 27
Activity of clindamycin with primaquine against Pneumocystis carinii in vitro and in vivo.
1988 Jun
Isolation and characterization of rat lung Pneumocystis carinii gp120.
1991 Nov-Dec
Inhibitors of human immunodeficiency virus integrase.
1993 Mar 15
Efficacy of 101 antimicrobials and other agents on the development of Cryptosporidium parvum in vitro.
1996 Dec
Potential inhibitors of HIV integrase.
1999 Apr-May
Primaquine-induced hemolytic anemia: formation and hemotoxicity of the arylhydroxylamine metabolite 6-methoxy-8-hydroxylaminoquinoline.
2001 May
Primaquine-induced hemolytic anemia: role of membrane lipid peroxidation and cytoskeletal protein alterations in the hemotoxicity of 5-hydroxyprimaquine.
2005 Aug
Evaluation of anti-malarial effects of mass chemoprophylaxis in the Republic of Korea army.
2005 Oct
[Haemolysis due to primaquine in 3 cases].
2006 Feb 28
Pharmacokinetics of piperaquine after repeated oral administration of the antimalarial combination CV8 in 12 healthy male subjects.
2006 May
Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I.
2006 Sep
Development and validation of UPLC method for determination of primaquine phosphate and its impurities.
2008 Jan 22
Formulation and evaluation of primaquine phosphate taste-masked rapidly disintegrating tablet.
2008 Oct
In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) individuals.
2010 May
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
2011 Jul 14
Quinolin-4(1H)-imines are potent antiplasmodial drugs targeting the liver stage of malaria.
2013 Jun 13
Patents

Sample Use Guides

Patients recieved 25 mg once daily for 7 days.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Name Type Language
PRIMAQUINE
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
PRIMAQUINE [VANDF]
Common Name English
PRIMAQUINE [MI]
Common Name English
SN-13272
Code English
(±)-PRIMAQUINE
Common Name English
Primaquine [WHO-DD]
Common Name English
KANAPRIM
Brand Name English
WR-2975
Code English
PRIMACHIN
Common Name English
NEO-QUIPENYL
Brand Name English
MALIRIDE
Brand Name English
NSC-27296
Code English
primaquine [INN]
Common Name English
QUINOLINE, 8-((4-AMINO-1-METHYLBUTYL)AMINO)-6-METHOXY-
Systematic Name English
1,4-PENTANEDIAMINE, N4-(6-METHOXY-8-QUINOLINYL)-
Systematic Name English
Classification Tree Code System Code
LIVERTOX NBK548031
Created by admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
WHO-ATC P01BA03
Created by admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
NDF-RT N0000175482
Created by admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
NCI_THESAURUS C271
Created by admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
WHO-ESSENTIAL MEDICINES LIST 6.5.3.1
Created by admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
Code System Code Type Description
EVMPD
SUB10043MIG
Created by admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
PRIMARY
MESH
D011319
Created by admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
PRIMARY
FDA UNII
MVR3634GX1
Created by admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
PRIMARY
PUBCHEM
4908
Created by admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
PRIMARY
SMS_ID
100000081655
Created by admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
PRIMARY
ECHA (EC/EINECS)
201-987-2
Created by admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
PRIMARY
ChEMBL
CHEMBL506
Created by admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
PRIMARY
CAS
90-34-6
Created by admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
PRIMARY
NSC
27296
Created by admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
PRIMARY
CHEBI
8405
Created by admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
PRIMARY
EPA CompTox
DTXSID8023509
Created by admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
PRIMARY
DRUG CENTRAL
2266
Created by admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
PRIMARY
DAILYMED
MVR3634GX1
Created by admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
PRIMARY
WIKIPEDIA
Primaquine
Created by admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
PRIMARY
CAS
57152-47-3
Created by admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
SUPERSEDED
NCI_THESAURUS
C62071
Created by admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
PRIMARY
HSDB
6516
Created by admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
PRIMARY
MERCK INDEX
m9133
Created by admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
PRIMARY Merck Index
LACTMED
Primaquine
Created by admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
PRIMARY
RXCUI
8687
Created by admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
PRIMARY RxNorm
DRUG BANK
DB01087
Created by admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
PRIMARY
INN
218
Created by admin on Fri Dec 15 15:46:25 UTC 2023 , Edited by admin on Fri Dec 15 15:46:25 UTC 2023
PRIMARY